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Abstract
Background. Cutaneous psoriasis and psoriatic arthritis increase the risk of cardiovas-
cular diseases though the reasons are not clear. Here we discuss the role of the immune 
system in atherosclerosis and of the proinflammatory status in psoriasis and psoriatic 
arthritis diseases.
Methods. We performed a Pubmed query covering publications within the last ten years 
including epidemiological studies, cross-sectional case-control studies, and reviews. 
Articles were selected according critical associations using arthritis, immune-mediated 
inflammatory diseases, and psoriasis as key fields. These were crossed and combined with 
atherogenesis, endothelial dysfunction, intima-media thickness, subclinical atherosclero-
sis, plaque, thrombosis, thrombus, fibrinolysis, coagulation, and reactive oxygen species, 
all closely related to cardiovascular diseases. Both types of disease selected terms were sep-
arately combined with cardiovascular risk factors both non-traditional (innate and adap-
tive pro- and anti-inflammatory immune molecules and cells), and traditional (metabolic 
conditions and related molecules).
Results and conclusions. Immune-activated crossroads came out as the main con-
tributors to proatherogenic inflammation in psoriasis and psoriatic arthritis disease. 
Traditional and non-traditional cardiovascular risk factors´ interactions result from 
an active cross-talk between proatherogenic mediators derived from metabolic, vas-
cular and autoimmune joint and skin inflammation in target tissues. Consistently, 
psoriasis and psoriatic arthritis diseases offer an invaluable scenario to deepen our 
knowledge on atherosclerotic cardiovascular disease.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: psoriasis, psoriatic arthritis, inflammation, immune system, cardiovascular 
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1. Introduction
Traditional cardiovascular risk factors like smoking, diabetes mellitus, hypertension, and 
hypercholesterolemia can barely account for the high prevalence of cardiovascular disease.
At the beginning of the last century, Nikolai N. Anichkov demonstrated that cholesterol per 
se was able to produce atheromatous lesions in the vascular wall [1]. He also described the 
presence of inflammatory cells in the lesions, but these findings were dismissed for many 
decades. In 1995, Hansson and others established that atherosclerosis exhibited many features 
of a chronic inflammatory process, giving rise to the immune-mediated hypothesis behind ath-
erogenesis [2]. At the time, however, preventive medicine was not a priority. Nowadays, such 
discoveries can be highly valuable in immune-mediated inflammatory disorders (IMID) in 
general, and in psoriasis (Ps) and psoriatic arthritis (PsA) in particular. It is known that adap-
tive and innate immunity participate in every step of atherogenesis. In fact, both traditional 
and non-traditional cardiovascular risk (CVR) factors increase in the course of these diseases 
[3]. This provides a comprehensive basis to explain the immune-mediated nature of atherogen-
esis beyond autoimmune condition while outlining the different crossroads of inflammation.
2. Psoriasis and psoriatic arthritis
Psoriasis (Ps) and psoriatic arthritis (PsA) belong to the family of IMID, affecting predomi-
nantly skin and joints. The prevalence of Ps varies between 2 and 3% worldwide with a similar 
distribution according to sex [4]. Epidemiological studies show peak incidence between the 
second and third decades in life [5]. It has been estimated that 7–42% of Ps patients develop 
inflammatory arthropathy, usually manifesting as a mono or asymmetrical oligo-arthritis 
[6]. Substantial body of evidence suggests that PsA patients are at higher risk of developing 
atherosclerotic cardiovascular disease (CVD) [7–9] and mortality [10, 11]. To date, the patho-
genesis of Ps and PsA remains unknown. Autoantigens have not been identified and the spec-
ificity of infiltrating lymphocytes is still unknown [2]. Genetically predisposed background 
and several suspected environmental triggering factors (e.g., infections, drugs, physical, and 
emotional stress) have been implicated in the initial stages of these diseases [9]. PsA is consid-
ered a seronegative (rheumatoid factor negative) arthritis. In Ps and PsA, the inflammatory 
features/reactions in skin and joints are very similar regarding composition of inflammatory 
infiltrates and vascular changes as explained in Figure 1 [12]. Moreover, the cellular infiltrate 
is predominantly perivascular and due to mononuclear cells [13].
The contribution of B lymphocytes to Ps and PsA pathogenesis is poorly understood. However, 
none of the forms of Ps or PsA have been associated with serum auto-antibodies [14]. In con-
trast, T lymphocytes are the most abundant in both skin and the synovial fluid of joints, with 
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predominance of Tc1 (subpopulation of CD8+ cytotoxic T cells that secrete interferon (IFN) 
and IL-4), T-helper 1 lymphocyte subpopulation (Th1) and Th17 (IL-17+ T-helper cells) which 
interact with dendritic cells, macrophages, and target tissue cells [15]. Positive chemotaxis 
is observed between these cells and MCP-1 as found in synovial fluid [16] and skin biopsies 
obtained from Ps and PsA patients [17]. The role of lymphocytes in Ps and PsA pathogenesis 
is discussed later.
3. Atherosclerosis
Atherosclerosis is a complex inflammatory disease characterized by disturbances in the meta-
bolic and immune system homeostasis that lead to pathogenic chronic progressive vascular 
damage and production of atherosclerosis plaque containing macrophages, lymphocytes, and 
other immune cells.
Classical knowledge distinguishes between inflammatory and non-inflammatory diseases. 
However, this distinction is no longer appropriate following the identification of inflamma-
tory mechanisms associated with the traditionally called “non-inflammatory diseases.”
Figure 1. Schematic representation of the immune system-derived crosstalk between IMID and metabolic tissue, 
with events that worsen cardiovascular risk profile. Chronic inflammation of the skin and joints have many common 
immunopathological features, including genetic predisposition, composition of inflammatory infiltrates, vascular 
changes, early immune events, and proangiogenicity. Antigen is presented to naive CD4 T cells during immune synapse 
in the lymph node. Emerging lymphocytes migrate preferentially to skin and joints, where the above-mentioned 
infiltrating T lymphocytes (CD4 and CD8) interact with local APC (Langerhans cells, myeloid-DC, and plasmacytoid-DC) 
to produce chronic inflammatory conditions. Local re-activated T cells secrete chemokines and cytokines that amplify 
the inflammatory environment, resulting in the formation of psoriatic plaque, induction of cartilage degradation, 
and perhaps formation of atherosclerotic plaque. Since the suppressive activity of regulatory T cells is decreased in 
both tissue and blood, chronic production of proinflammatory cytokines (IFN-γ and TNF-α) crucially contributes to 
perpetuate the disease. In addition, deregulated adipose tissue (WAT) that secretes cytokines and chemokynes enhances 
systemic inflammatory burden leading to metabolic diseases (diabetes, metabolic syndrome, and dislipemia).
Immune System Links Psoriasis-Mediated Inflammation to Cardiovascular Diseases via Traditional...
http://dx.doi.org/10.5772/intechopen.68559
93
Although atherogenesis belonged to this group for several decades, now it is confirmed that 
the immune system acts on the endothelial wall and triggers an inflammatory cascade, lead-
ing to a progressive low-grade inflammatory process of the arterial vascular wall in response 
to accumulation and oxidation of lipoproteins. Yet, further considerations pinpoint a promi-
nent and severely pathogenic role of the immune system in these diseases [18].
Studies in hypercholesterolemia-induced immune activation in mouse models of atheroscle-
rosis highlight the critical balance between Th1 cells [19] and Treg [20]. Inflammation in the 
intima layer appears to be related with protective and pathogenic immune responses against 
modified self-antigens in the atherosclerotic plaque [21].
The paradigm of atherosclerosis as an inflammatory disease is widely accepted. Interestingly, 
systemic inflammatory rheumatic diseases might share several immune-mediated inflam-
matory pathways with atherosclerosis. In fact, molecules and cells from innate and adap-
tive immune system (described below) mediate chronic inflammatory pathways activation 
derived from both diseases interacting in a positive feedback pathogenic circuit.
Increasing evidence suggests that even in clinically heterogeneous diseases, both of them could 
share common immunological pathways that might damage the cardiovascular (CV) system 
(Table 1). The contribution of chronic inflammation to CVR has mainly been investigated 
in rheumatoid arthritis (RA), the prototypical inflammatory disorder [22–24]. Consistently, 
Author, year Number of patients and study profile Findings
Han et al., 2006 [33] 3066 PsA patients vs. clinically 
asimptomatic controls matched by 
age, sex, and geographic region.
Higher prevalence for CHF, PVD, IHD 
atherosclerosis, type II diabetes, HL, and 
HTN in PsA patients than controls.
Sattar et al., 2007 [34] 127 patients with active Ps/PsA after 
at least first failure with DMARDS 
treatment, PsA- with 6 months 
duration or more with active arthritis 
in 3 or 4 swollen joints. Double-
blind placebo (n = 42) controlled 
study performed with two doses of 
Onercept for 12 weeks. 
Result compared against baseline before 
and after the end of treatment with 
Onercept. Results indicate higher CRP, 
that positively correlate with reduced 
Lp (a); higher ICAM-1; reduced IL6; 
reduced Homocysteine; same levels 
Apo-I¸ higher Apo-B, and higher TG.
Gonzalez-Juanatey et al., 2007 [35] 59 PsA patients vs. 59 control 
patients without clinically evident 
CVD adjusted for age and ethnia.
Carotid artery IMT correlated with age, 
time of PsA diagnosis, disease duration, 
total cholesterol, and LDL.
Eder et al., 2008 [36] 40 PsA patients compared with 40 
controls matched by age, sex, and 
CVR factors.
Multivariate analysis indicates that 
PsA status, age, and TG levels were 
associated with IMT and carotid plaque.
Tam et al., 2008 [37] 102 PsA patients from Southern 
China.
Increased prevalence of DM and HTN 
was found in PsA group compared with 
age- and sex and BMI-matched controls.
Kimhi et al., 2007 [38] Carotid artery IMT from 47 patients 
with PsA were compared with 43 
healthy controls matched for age 
and sex.
The average IMT (mean/standard 
deviation) in PsA patients was 
significantly higher compared to CP 
even after adjustment for age, GR, BMI, 
HTN, and HL.
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chronic activation of immune-mediated pathways is believed to accelerate or trigger critical 
atherosclerosis events in Ps and PsA.
A multidisciplinary expert committee was designated a few years ago in accordance with 
European League against Rheumatism (EULAR) suggests apart from the management of 
conventional risk factors, an aggressive inflammation suppressive therapy to further reduce 
[3] death in PsA patients [25]. Chronic inflammatory state seems to be the potential driv-
ing force behind the accelerated atherogenesis [26]. In this regard, few papers have been 
published related to CVR factors (Table 1) [7, 8, 27]. Some representative prospective and 
Author, year Number of patients and study profile Findings
Gladman et al., 2009 [39] 648 patients with Ps and PsA. Enhanced CV risk. Severity of skin 
involvement is an independent CVR 
factor.
Shang et al., 2011 [40] 94 PsA patients without clinical 
evidence of CVD and 63 healthy 
subjects.
PsA patients without established CVD 
and in the absence of TRF have a high 
prevalence of subclinical ED via imaging 
studies.
Eder et al., 2013 [29] Cross-sectional study comparing 125 
PsA with 114 Ps patients.
PsA patients suffer from more severe 
subclinical atherosclerosis compared 
with Ps patients.This difference is 
independent of CVR factors.
Ogdie et al., 2014 [27] Longitudinal cohort study comparing 
8706 PsA, 41,752 RA, 138,424 Ps and 
82,258 controls.
Patients with RA and Ps have increased 
mortality compared with the GP but 
patients with PsA do not.
Svedbom et al., 2015 [41] The study compared the risk of death 
in 39,074 patients with mild and 
severe psoriasis vs. 154,775 sex-, age-
matched referents.
Cardiovascular disease was the main 
driver of excess mortality patients with 
mild and severe psoriasis.
Cea-Calvo et al., 2016 [42] PSO-RISK was a cross-sectional, 
multicenter, single-visit study of 368 
patients (≥18) with Ps on systemic 
therapy. 
CVR factors were detected in 27.5% 
(n = 101) of patients with previously 
unknown cardiovascular risk factors.
Tejón et al., 2016 [43] The study compared age- and sex-
matched case-control study PsA 
patients who developed CV events 
during the study (2010–2014) vs. 
control group CV events.
Traditional CV risk factors as well 
non-inflammatory CV risk factors of the 
disease were the main predictors of CV 
complications in this PsA population.
AC: Alcohol consumption; BMI: Body mass index; CAD: Coronary artery disease; CCF: Controlled for confounding 
factors; CHF: Congestive heart failure; CP: Control population; CVD: Cardiovascular disease; DM: Diabetes 
mellitus; DMARDS: Disease-modifying antirheumatic drugs; ED: Endothelial dysfunction; GR: Gender: GP: General 
population; HDL: High-density lipoprotein; HL: Hyperlipidemia; HTN: Hypertension; ICAM-1: Intercellular adhesion 
molecule 1; IHD: Ischemic heart disease; IL6: Interleukin 6; LDL: Low-density lipoprotein; Lp (a): Lipoprotein A; MI: 
Myocardial infarction; OB: Obesity; PVD: Peripheral vascular disease; TC: Total cholesterol; TG: Triglycerides; TRF: 
Traditional risk factors; VLDL: Very low-density lipoprotein.
Table 1. Representative summary of epidemiological studies (prospective and retrospective) linking Ps to associated 
Cardiovascular Risk and Comorbidities (RCM), published between 2006 and 2016.
Immune System Links Psoriasis-Mediated Inflammation to Cardiovascular Diseases via Traditional...
http://dx.doi.org/10.5772/intechopen.68559
95
retrospective epidemiological surveys, published between 2006 and 2015 (Table 1), indicate 
that Ps and PsA patients exhibit higher prevalence of myocardial infarction (MI), ischemic 
heart disease, hypertension, diabetes, and dyslipidemia compared with normal controls. 
Although multiple CVR factors are associated with Ps, key components of the metabolic 
syndrome are more strongly connected with more severe Cutaneous psoriasis (PsC) [28]. 
Recent studies [29] suggest an increased inflammatory burden in PsA compared with Ps 
(Table 1). In contrast, the risk of developing a CV event (MI, ischemic stroke, and transient 
ischemic attack) was not elevated in early Ps patients in a matched follow-up study, case-
control analysis [30, 31].
4. Inflammatory and classical cardiovascular risk factors
4.1. Inflammatory risk factors
Since a substantial amount of data accumulates in the past of this issue, we provide a brief 
insight into the most common inflammation-related and non-inflammatory factors involved 
in accelerated atherogenesis in Ps and PsA. As previously mentioned, Ps and atherosclero-
sis have a similar immune innate and adaptive pathogenic hallmark and an active crosstalk 
between “traditional” or “non-traditional” (Figure 1) [32].
4.1.1. Innate immunity
Toll-like receptor 2 (TLR-2) and toll-like receptor 4 (TLR-4) trigger receptor-mediated events, 
including cytokine-mediated inflammation, are involved in atherosclerosis [44], Ps, and 
other pathologies [34]. TLR expression is positively correlated with plasma tumor necrosis 
factor-alpha (TNF-α) levels [45]. Cytokine-triggered TLRs activation is known to modulate 
major pathological processes, including inflammation, angiogenesis, tissue remodeling, and 
fibrosis. Although joints are the most obvious inflammation sites in PsA, proinflammatory 
cytokines, most likely TNF-α and interleukin 6 (IL-6), are released in blood circulation and 
act on distant organs (immune system, adipose tissue, liver, hematopoietic tissue, skeletal 
muscle, glands, and endothelium). These effects are linked to systemic inflammation and lead 
to a proatherogenic profile. Cytokines orchestrate endothelial adhesiveness, matrix metallo-
proteinases (MMPs) activation, reactive oxygen species (ROS) production, C-reactive protein 
(CRP), fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) release [46].
Indeed, atherogenic lipid alterations, oxidative stress abnormalities, vascular injury repair 
failure, arterial stiffness, insulin resistance induction, endothelial dysfunction, hypercoagulable 
state, homocysteine elevation, and pathogenic T cell up-regulation could all be attributed in 
part to the proinflammatory actions of cytokines. Common inflammatory mechanisms in Ps 
and atherosclerosis may be related to other factors by the high number of overlapping mol-
ecules, including cytokines [interleukins (IFN-α, IL-2, IL-6, IL-10, IL-13, IL-15, IL-17, IL-18, 
IL-20, and IL-23)], interferon alpha (IFN-α), Oncostatin M, (TNF-α), chemokines [Fractalkine, 
growth-regulated oncogene (GRO) alpha], CCL-3(MIP-1α), CCL-4 (MIP-1α), CCL-11 
(Eotaxin), IL-8, MCP-1, monokine induced by interferon gamma (MIG/CXCL9), adipokines 
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(Resistin, Leptin, and PAI-1), adhesion molecules (ICAM/LFA-1(leukocyte function-associated 
antigen-1), CD154 (OX40L)/CD134 (OX40), epidermal growth factor (EGF), vascular endothe-
lial growth factor (VEGF), fibroblast growth factors (FGF), and GCSF, co-stimulatory mol-
ecules (CD80, CD28, and CD40/CD40L), lymphocyte profile Th1/Th17 up-regulation, Treg 
down-regulation, CTL effect or activity, NK cells, natural killer T (NKT) cells, myeloid den-
dritic cells, plasmacytoid dendritic cells, monocytes/macrophages, mast cells and neutrophils, 
complement activation [47], TLR-mediated inflammation (TLR-2, TLR-4, and TLR-9) [27–29], 
and other important factors, such as CRP, endothelin-1, inducible nitric oxide synthase 
(iNOS), heat shock protein (HSP60, HSP65, and HSP70), matrix metalloproteinases (MMP-2 
and MMP-9), and oxidized low-density lipoprotein (LDL) [45, 48, 49]. Some molecules listed 
before and other PsA-related serum cytokine patterns have been demonstrated by multiplex 
cytokine array systems in Norwegian PsA patients [50, 51]. Few of these cytokines previously 
mentioned [52, 53] and their pathogenic contribution at different stages in the pathobiology 
of atherothrombosis and PsA are not clear yet [36].
NK cells increase the susceptibility to PsA [51] and the inflammatory infiltrate in psoriatic 
skin lesions. Although more studies must be done, emerging evidence supports a role for NK 
cells in Ps. Inverse correlation exists between NK cell population and body mass index (BMI). 
Therefore, adipose immune cell phenotype and function may provide greater insight into 
cardio-metabolic pathophysiology in psoriasis [54, 55].
NKT cells are a heterogeneous subset of T cell lineage lymphocytes that bear NK cell mol-
ecules and T cell receptors, which recognize microbial glycolipids and their own endogenous 
mammalian lipids presented by the MHC I-like molecule (CD1d) and have been implicated 
in the pathogenesis of various autoimmune diseases including Ps. Due to the numerous func-
tions of NKT cells that link innate and adaptive immunity, their role in Ps is complex and still 
elusive. ApoE and LDL receptors have been involved in antigen uptake for presentation to 
NKT cells [56] NKT cells may represent a potential new therapy for atherosclerosis [57].
Our knowledge of biologically active serum molecules and cells involved in the pathogenesis 
of both PsA and atherosclerosis is still not clear enough. Taken together, cytokines seem to 
play a pivotal role as the major link between PsA and atherosclerosis. Compiled data show 
that untreated PsA inflammation could produce damage to the CV system even before it 
affects the joints [50]. Current evidence suggests that the pathway of inflammation in athero-
sclerosis culminates in altered concentrations of various markers in peripheral blood, includ-
ing oxidative stress molecules [58–60] and markers of vascular inflammation like CRP [59], 
IL-6, ICAM-1, and MCP-1 [61].
4.1.1.1. Tumor necrosis factor-α
The pleiotropic cytokine TNF-α is among the most potent mediators of inflammation. Circulating 
T lymphocytes and monocyte-derived macrophages isolated from PsA patients produce 
increased amounts of TNF-α in comparison with macrophages isolated from healthy controls 
[8]. Furthermore, levels of TNF-α in PsA patients are elevated in the synovial tissue and skin 
lesions and correlate with disease activity. TNF-α is a key regulator of vascular homoeostasis 
[34], leading to proatherogenic effects, lipid abnormalities, including high LDL cholesterol 
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and low HDL cholesterol [62], hypercoagulable state via induction of cell surface expres-
sion of tissue factor (TF) on the endothelial wall and suppress anticoagulant activity via the 
thrombomodulin-activated protein C system [63]. The majority of epidermal CTL and Th1 
effector lymphocyte populations and molecules are elevated in Ps vulgaris lesions and in cir-
culating blood in psoriatic patients [64]. TNF-α also induces endothelial dysfunction includ-
ing low nitric oxide availability and up-regulation of endothelial adhesion molecules such as 
vascular cell adhesion molecule 1 (VCAM-1) [65, 66], a critical early step in atherogenesis. On 
the other hand, TNF-α blockade leads to a significant decrease in the levels of lipoprotein a 
(Lpa) homocysteine and an increase in apolipoprotein A-I (Apo A-I), triglyceride, and Apo-B 
concentration [62]. Long-term use of TNF-α blocking agents interferes with TNF-α function 
reducing the high incidence of cardiovascular events and associated vascular complications 
in CV diseases [67]. Taken together, the above-mentioned studies confirm a critical role for 
TNF-α in altering a number of well-studied putative vascular, thrombotic, and metabolic risk 
parameters (lipids and lipoproteins).
4.1.1.2. Interleukin 6
As an inflammatory cytokine, IL-6 regulates chemokine-directed leukocyte trafficking and 
directs transition from innate to adaptive immunity through the regulation of leukocyte 
activation, differentiation, and proliferation [68]. During acute and chronic inflammatory 
response, macrophages release TNF-α in the presence of a great variety of stimuli, including 
atherogenic and poorly characterized arthritogenic factors. TNF-α action on macrophages 
triggers the release of more TNF-α and IL1-β, which stimulate endothelial cells to produce 
IL-6 and IL-8. IL-6 and their signaling events contribute to hepatic release of acute-phase 
reactants including CRP levels, atherosclerotic plaque development and destabilization [69, 
70]. IL-6 may also contribute to atherosclerosis and arterial thrombosis by activating the pro-
duction of tissue factor, fibrinogen and factor VIII; increasing endothelial cell adhesiveness 
and stimulating platelet production and aggregation [71]. In addition, IL-6 is produced by 
smooth muscle cells (SMC) of many blood vessels and by adipocytes and, together with CRP 
and TNF-α, is involved in metabolic syndrome pathophysiology, insulin resistance [72] and 
coronary artery disease and the risk of MI [73–76], and cardiovascular mortality [77]. In addi-
tion, IL-6 locally produced in the endothelium and in SMC is an important autocrine and 
paracrine regulator of SMC proliferation and migration. IL-6 decreases cardiac contractility 
via a nitric oxide (NO)-dependent pathway activating STAT3-dependent anti-inflammatory 
signal transduction [78].
Numerous studies show a strong association between IL-6 and joint immune-mediated dis-
eases. In the joint, macrophages and mast cells trigger a proinflammatory cascade in the pres-
ence of unknown stimuli, releasing great amounts of TNF-α, which induce the expression 
of IL-1 and IL-6. Mice deficient in mast cells are comparatively resistant in experimentally 
induced arthritis. In addition, it is a major promoter of bone resorption in pathological condi-
tions [79]. In particular, IL-6 has a pivotal role in synovitis, bone erosion, and in the systemic 
features of inflammation [80].
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In Ps, most available evidence indicates that the pathogenic action of IL-6 is important. In 
fact, IL-6 co-localizes with CD45+ perivascular cells within lesional tissue and reverses the 
suppressive function of human T-regulatory cells [81].
The successful treatment of certain autoimmune conditions with the humanized antibody 
anti-IL-6 receptor (IL-6R) (Tocilizumb) has emphasized the clinical importance of cytokines 
that signal through the β-receptor subunit glycoprotein 130 [82].
IL-6 may, in both cardiovascular and joint-diseases involving Th1/Th17 mechanisms, alter the 
balance between the effector and regulatory arms of the immune system and drive a proin-
flammatory phenotype reinforcing innate and adaptive immune-mediated positive feedback 
[83], potentiating the immune effector mechanism. In both arterial disease and Ps/PsA, IL-6 
seems to be a critical mediator of long-term chronic inflammation and to have deleterious 
effect in the arterial wall and in the joint.
4.1.1.3. Endothelin-1
The family of endothelins (ET) includes three 21-aminoacid isoforms endothelin-1 (ET-1), endo-
thelin-2 (ET-2), and endothelin-3 (ET-3), which have endogenous pressor activity and are 
secreted by different tissues and cells. In addition, ET-1 is a vasoactive peptide that induces 
vasoconstriction, inflammation, and fibrosis and has mitogenic potential for SMC [84]. In the 
skin, ET-1 participates in keratinocyte proliferation, neoangiogenesis, and chemotaxis. Its lev-
els are elevated in psoriatic lesions and serum of patients with Ps [85]. Synovial tissue and 
serum of patients with PsA all show strongly enhanced ET-1 receptor expression [86].
4.1.1.4. C-reactive protein
A considerable amount of evidence implicates C-reactive protein (CRP) as a predictive 
marker for future CV events and mortality in different settings, particularly under metabolic 
syndrome conditions in the general population [87, 88]; CRP has also been implicated as a 
direct partaker [7, 89, 90]. In addition, CRP stimulates the production of plaque destabilizing 
MMPs and MCP-1, a decrease in the activity of endothelial nitric oxide synthase (eNOS) and 
impairment in endothelium dependent vasodilation [91]. In vitro, studies provide evidence 
for direct proatherogenic effects of CRP, including increased endothelial dysfunction [92]. 
Baseline CRP levels were elevated in patients with Ps with and without psoriatic arthritis and 
Etanercept, a biologic TNF antagonist, treatment may reduce CRP levels in both groups [93].
4.1.1.5. Adipokines
Interestingly, in metabolic disorders associated with Ps/PsA, inflamed adipose tissue may 
enhance inflammatory proatherogenic status via adipokine production (leptin, adiponectin, 
and resistin) and cytokine (TNF-α and IL-6) secretion. Adipose tissue influences both natural 
and adaptive immunities and links inflammation, metabolic dysfunction, and cardiovascular 
disease [94].
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4.1.1.6. Matrix metalloproteinases (MMPs)
MMPs are endoproteases with collagenase and/or gelatinase activity which exert deleterious 
effects on the endothelium integrity and collagen fibers, promoting atherosclerotic plaque 
destabilization and accelerating the process of atherothrombosis [95]. MMP-1 serum levels 
and gene expression are elevated in PsA [96].
4.1.2. Adaptive immunity
As previously mentioned, Ps/PsA and atherosclerosis share certain common underlying 
pathogenic inflammatory mechanisms. Specifically, both are associated with Th1 and CTL 
(cytotoxic T lymphocyte) effector cell-mediated events in vivo [68], and are elevated in circu-
lating blood [63]. In contrast, the T-regulatory activity is reduced.
4.1.2.1. Cellular immune response
Myeloid dendritic cells can stimulate both memory and naive T cells, and are the most potent 
of all the antigen-presenting cells in normal and various pathophysiological conditions [97]. 
In turn, activated T cells undergo firm adhesion and transendothelial migration to inflamma-
tory focus. Extravasation is orchestrated by the combined action of cellular adhesion recep-
tors and chemotactic factors in a wide variety of cardiovascular and autoimmune disorders 
that involve inflammation.
The development and maintenance of psoriatic plaque are dependent on the participation 
of infiltrating T lymphocytes (CD4 and CD8) and local antigen-presenting cells (APCs) 
(Langerhans cells, myeloid, and plasmacytoid-DC). DCs are increased in psoriatic lesions and 
are critically involved in the induction of Th1 and Th17 cell proliferation, which, in turn, 
release IFN-γ and IL-17, respectively. Activated mDCs produce IL-23 [98, 99] and TNF-α. 
IL-23 stimulates the secretion of IL-22 by Th17 cells, which may be involved in epidermal 
hyperplasia [5]. The effects of IL-17A-producing T-helper 17 (Th17) cells include suppressive 
effects of T-regulatory (Treg) subsets, which have also been implicated in both pathologies. 
The association of IL-17A with Ps and PsA has been extensively described [98, 99] and a 
growing body of evidence suggests that IL-17A might also be involved in atherosclerosis 
[100]. IL-17 seems to have a modulatory role in atherosclerosis, but studies available show 
contrasting results, which could be attributed to different approaches and models. Coronary 
syndrome correlates with increased IL-17 levels [101]. In addition, TNF-α and IL-17 synergis-
tically up-regulate further cytokine transcription in both diseases, Ps and atherogenesis [102]. 
These observations make IL-17A an interesting therapeutic target to modulate both PsA/Ps 
disease activity and atherosclerosis/cardiovascular risk. Obesity may play an important role 
by amplifying the inflammation of arthritis through the Th1/Th17 response [103]. Limited 
evidence from Ps patients indicates that induction therapy with infliximab, with moderate to 
severe plaque Ps, led to decrease in clinical disease scores and circulating levels of Th17, Th1 
cells, and associated TNF-α release [104].
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T cell activation is under control from T-regulatory immune cell (Treg) activity via IL-10 and 
TGF-β [105–107]. Reduced numbers and/or activity of Treg cells may produce hyperactivity 
of Th1/Th17 subsets in both pathologies [21, 108, 109]. Ps and coronary artery disease patients 
show impaired inhibitory function of Treg [110, 111]. Serum and epidermal levels [105, 106] of 
TGF-β in Ps patients are associated with Ps disease severity [112, 113] and are diminished in low 
Ps [5]. In atherosclerosis, high serum levels of TGF-β and IL-10 may inhibit plaque formation 
[114, 115] and plaque stabilization exerting protective effect due its inhibition of T cells [116].
4.1.2.2. Humoral immune response
Humoral response seems to protect rather than harm the host. Several lines of evidence sup-
port the hypothesis that humoral immunity protects patients against atherosclerosis. First, the 
injection of immunoglobulin preparations inhibits atherosclerosis. Second, spleen removal (a 
B-cell rich lymphoid organ) seems to deteriorate vascular disease condition. Third, oxidized 
LDL plus adjuvant immunization promote atheroprotection [2]. Evidence so far indicates that 
atheroprotection is due to a T cell dependent B-cell-mediated mechanism, probably involving 
antibody dependent clearance of LDL and humoral dependent regulation of pathogenic T cell 
[17]. This atheroprotective response must be confirmed in humans.
4.1.3. Genes related to the innate and adaptive immune system associated with psoriasis and 
atherogenesis
At least 10 chromosomal locus associated with psoriasis have been identified as PSORS (PSORS, 
psoriasis susceptibility) [117]. Additionally, certain human leucocyte antigen (HLAs) are more 
common in psoriatic arthritis. HLA alleles that are specific for psoriatic arthritis are HLA-B27 
and possibly HLA-B7, HLA-B38, and HLA-B39.
There is a strong association of psoriasis with the HLA-Cw6 allele, which increases 10–20 
times the risk of psoriasis and is present in 90% of the patients with early onset psoriasis and 
in 50% of those with late onset psoriasis [118].
Some molecules of the innate immune system have an important influence on the pathophysi-
ology of psoriasis, such as TLR2 and TLR4 play a key role in the pathogenesis of autoimmune 
diseases, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, 
Sjogren's syndrome, psoriasis, multiple sclerosis, and autoimmune diabetes [119].
Additionally, the expression of TLR2 and TLR4 correlates with the degree and severity of 
coronary disease [120, 121] oxidized phospholipids stimulate the TLR signaling pathway to 
induce inflammatory cytokine secretion by macrophages and endothelial cells [122].
Anti-CD14 and anti-TLR antibodies significantly inhibit the binding of fluorescein-labeled LDL 
to monocytes and interfering with cytokine release [123]. TNF-binding proteins are encoded 
by genes unrelated to PSORS, conferring susceptibility to psoriasis. Tumor necrosis factor, 
alpha-induced protein 3 (TNFAIP3) and tumor necrosis factor interacting protein 1 (TNIP1) 
are related to the inflammatory signal NF-κB, which regulates the release of TNF-α [124, 125].
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TNFAIP3 promotes the survival of T-CD4 lymphocytes [126]. Certain cytokine genes have 
been implicated with psoriasis, including IL-12, IL-23, IL-4/IL-13 [127] conferring an increased 
risk of psoriatic arthritis [128].
These genes strengthened the assertion that psoriasis is an immune disorder, as these genes 
are linked to both the innate and adaptive immune response [129–131]. In summary, defects 
in these genes could amplify an inflammatory response by interfering with normal negative 
feedback of the NF-kB signal and therefore would link to psoriasis with other IMID and coro-
nary pathology.
4.2. Non-inflammatory risk factors
Ps, PsA, and atherosclerosis share disturbances in different metabolic pathways involv-
ing insulin-dependent diabetes mellitus (IDDM), dyslipidemia, hypertension, obesity, and 
mostly metabolic syndrome, which may be related to an increase in the prevalence of CVD to 
their capability of inducing inflammation on the endothelial lining to initiate the process of 
atherosclerosis. So far, no pathophysiological mechanism for this association has been identi-
fied [63].
4.2.1. Hypertension
Several studies have found an increase in the prevalence of hypertension in Ps patients, although 
the definition of hypertension is very heterogeneous among these studies [117–121, 132]. Other 
authors have not observed a significant association between Ps and hypertension [122].
4.2.2. Diabetes mellitus
IDDM is responsible for metabolic alterations, accompanied by chronic inflammation and 
endothelium dysfunction. Observational studies show that the risk of IDDM is higher in 
patients with Ps compared with a healthy control group. This risk increases with the dura-
tion and severity of Ps and it is not related to a high body mass index (BMI) alone [133]. In 
a case-control study from Israel, the risk of diabetes was significantly higher in individuals 
with Ps [124]. Similarly, PsA patients have a higher prevalence of IDDM, even after adjusting 
for the BMI [125]. TNF-α antagonist therapy in patients with Ps seems to improve insulin 
sensitivity in limited preliminary data [126]. Finally, a few isolated cases of Ps patients with 
diabetes develop unpredictable hyperglycemia after starting treatment with TNF-α inhibi-
tors [127].
4.2.3. Obesity
Recent studies have shown that obesity may precede the onset of Ps as a risk factor [120], 
whereas a higher BMI is associated with more severe skin disease activity [3]. The influence of 
obesity on psoriatic diseases is the result of complex interactions of inflammatory and meta-
bolic factors. The proinflammatory cytokines stimulate adipocytes to synthesize neuropep-
tides and more cytokines, which are critical in the pathogenesis of the psoriatic and CVD [69].
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4.2.4. Smoking
Heavy and long-term smoking [128] have been associated with increased Ps risk in both men and 
women [129], particularly pustular Ps [116, 117, 120]. Smoking increases oxidative damage, pro-
motes inflammatory changes, and enhances Ps-associated gene expression [121] and CVR [50, 122].
4.2.5. Dyslipidemia
Ps patients have a higher prevalence of dyslipidemia and triglycerides and lower prevalence 
of HDL levels. However, associations with total cholesterol and LDL have not been found 
statistically significant in a multivariate analysis study [116–118].
4.2.6. Metabolic syndrome
The metabolic syndrome consists of a constellation of clinical features involving abdominal 
obesity (waist circumference from >94 cm in men and >80 cm in women), and two or more of 
the following clinical situations:
HDL ≤ 40 mg/dl in men and 50 mg/dl in women, TG > 150 mg/dl, fasting blood glucose > 100 mg/
dl, blood pressure > 130/85 mm Hg or treatment for hypertension. The metabolic syndrome is 
characterized by increases in the immunological activity of Th1, which suggests it may be associ-
ated with Ps because of shared inflammatory pathways.
Gisondi et al. [134] reported that, among Ps patients without systemic medication, 40-year-old 
and older people have a higher prevalence of metabolic syndrome [124].
Recently, Raychaudhuri et al. observed an increased prevalence of metabolic syndrome in patients 
with PsA; DM type 2 [58] and increased risk for CVD and mortality [125–129]. Ps with metabolic 
syndrome [130] associates with high serum uric acid levels that correlate with an increased risk 
of carotid intima-media thickness (IMT) or with the presence of carotid plaques [131].
5. Common angiogenic factors for Ps and atherosclerosis
Angiogenesis appears to be pathological in some chronic inflammatory diseases, like Ps and 
RA. It is possible for reactive homeostatic or pathological angiogenesis to play an important 
role in atherosclerosis. Serum levels of proangiogenic cytokines (TGF-β, TNF-α, IL-8, and 
IL-17), growth factors, including VEGF, and hypoxia-induced factor-1 have been shown to be 
significantly elevated in Ps patients compared to healthy controls [132, 133].
6. Oxidative mechanisms common to atherosclerosis and Ps
Cellular deregulation and damage [51] could be the result of overproduction or insufficient 
removal of ROS. In the skin, ROS can be generated either endogenous or exogenously. 
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Endogenously, ROS are produced through the electron transport chain and enzymes, such 
as cyclooxygenases (COX) [33], lipoxygenases [38], NADPH oxidases [135], and myeloper-
oxidases [39]. Exogenous sources that trigger ROS production include UV radiation and 
heavy metals [51]. In Ps, antioxidant defense mechanisms seem to be impaired, including 
superoxide dismutases (SODs), glutathione peroxidases, glutathione reductase, catalase, 
thioredoxin/thioredoxin reductase system, and metallothioneins. Augmented ROS produc-
tion in the skin leads to downstream molecular events that promote atherosclerosis [51, 
136, 137].
The antioxidant activity of vitamin D is well known/widely characterized. The knowledge of 
non-classical functions emerges from studies that indicate a close association between a low 
vitamin D status and increased risk of IMID and CVD [138]. It is also known that vitamin D 
insufficiency induces metabolic, procoagulant, and inflammatory perturbations. Recent stud-
ies indicate that it also increases the risk of MI by promoting established CVR factor-mediated 
mechanisms that predispose to atherothrombosis [139].
Immunomodulatory role of vitamin D in human health implicates appropriate signaling for both 
innate and adaptive immune responses (T and B lymphocyte function) [140–142] that amplify 
inflammation in Ps [143] and promote the development of different types of Treg cells [144].
7. Some lessons from CVD and rheumatic-associated therapies
Whether antirheumatic therapies increase or decrease CV risk is controversial. Glucocorticoids 
(GCs) are known to cause hypercholesterolemia, hypertriglyceridemia, weight gain, hyper-
tension, and glucose intolerance, all factors promoting CVD. However, GCs are not ever con-
flicting. In RA patients with a known history of CVD, steroid therapy surprisingly attenuated 
the risk of CV death [145]. The mechanism of this apparent discrepancy with GC exposure is 
still unknown, but it seems to be related with dose, duration, and intensity of the exposure.
Although coronary artery disease and acute myocardial infarction are inflammatory disorders, 
the only drugs with anti-inflammatory effect so far widely used in ischemic heart disease are 
aspirin and statins (e.g., atorvastatin and simvastatin).
The contribution of coxibs and most nonsteroidal anti-inflammatory drugs (NSAIDs) to low-
ering CVR is not well established and the evidence available so far is controversial. Multiple 
studies provide evidence that methotrexate is protective against CV events and CV mortality, 
although the protective benefit is under discussion [146]. Immunomodulatory or immunosup-
pressive therapies, such as cyclosporine and colchicine, may have benefits in coronary artery 
disease [147]. Other studies have found that glucocorticoids plus cytotoxic immunosuppres-
sive agents (azathioprine, cyclosporine, and leflunomide) are associated with an increased 
amount of CV events when compared with methotrexate alone [148].
The new targeted biological therapies, such as the suppression of systemic inflammation by 
anti-TNF therapies, seem to be associated with concomitant reduction in the risk of CV events 
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[149], although the effect of TNF-α antagonists in lowering proatherogenic status needs further 
investigation. In addition, cardiovascular therapy drugs could change the proinflammatory 
status of PsA patients under treatment with 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors (statins), angiotensin converting-enzyme (ACE) inhibitors, and/or angiotensin II 
receptor antagonists (AT-II blockers). Hence, their prescription should be managed cautiously, 
especially for patients with a documented CV disease or in the presence of CVR factors.
Other drugs with potential benefits may include the thiazolidinedione (TZD) family, which 
produces positive effects on both CVR factors and Ps [14]. Targeted therapeutic interventions 
along with an effective control of the inflammation may have more beneficial CV effects than 
direct CV toxicity. There is a need for more studies addressing the role of current biological 
therapies on patients with a CV risk profile [3].
8. The central role of the immune system
Atherosclerosis is a complex disease but, as specific knowledge increases, the immune system 
can be clearly recognized to be involved in all steps of vascular pathology. Both classical 
and non-classical CVR factors are closely interconnected in the production of chronic inflam-
mation through loss of immune homeostasis; indeed, either molecules or cells involved in 
atherogenesis present altered regulatory and/or effector immune functions, attenuating and 
promoting atherogenesis.
Some authors have proposed an autoimmune origin in atherosclerosis [82, 83]. Immune sys-
tem homeostasis alterations against the patient’s own antigens and the increasing prevalence 
of atherosclerosis in immune-mediated diseases, such as diabetes, periodontal disease, sys-
temic sclerosis, antiphospholipid syndrome, RA, SLE, ankylosing spondylitis (AS), and PsA 
strongly reinforce the involvement of autoimmune mediators and the key role of inflamma-
tion in atherosclerosis [150]. This autoimmune response to oxidized LDL is a driving force 
for cell activation in the human atherosclerotic plaque [151]. The fact that low and high grade 
chronic inflammatory disorders present an accelerated progression of atherosclerosis consti-
tutes indirect but critical evidence that strengthens the above-mentioned immune-mediated 
inflammation. The Ps/PsA proatherosclerotic profile seems to be related to chronic inflam-
mation through classical and non-classical factors. Important insights reviewed in this article 
indicate that most, if not all inflammatory factors, are the result of immune activation and 
cytokine-driven inflammation.
For example, Th1, CTL, and Th17 effector cells are the dominant types in the pathogenesis 
of the psoriatic and cardiovascular diseases and are the most abundant T lymphocytes in 
skin, joints, and human atherosclerotic plaque [63]. In addition, reduced levels of circulating 
anti-inflammatory mediators and Treg may increase CV risk in both diseases [146, 152] induc-
ing up-regulation of adhesion molecules [153] and promoting a more procoagulant [154] and 
vasoconstrictor phenotype [155]. Although anti-atherogenic humoral response could be veri-
fied, its anti-atherogenic action must be confirmed [2].
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Indirect evidence indicating that immune-mediated inflammation is a key regulator in the cross-
road of pathogenesis between Ps/PsA and atherogenesis derives from the role of certain thera-
pies. Some drugs used in the treatment of CV disease, such as statins and ACE inhibitors, have 
anti-inflammatory activity. In addition, systemic treatments for Ps that decrease inflammation 
also reduce CV risk [156]. TLRs are the best candidates to explain what triggers and sustains the 
natural and adaptive immune response, maintaining proinflammatory cytokine gene expression 
in chronic inflammation, worsening atherosclerosis [145] in general population and in Ps patients.
Finally, the role of obesity, metabolic syndrome (possible via hypertriglyceridemia and asso-
ciated abdominal adiposity in Ps/PsA patients), and probably DM, in this scenario of severe 
Ps and accelerated CVR. Adipose tissue is not just an “endocrine organ.” Now, we know adi-
pocytes express TLRs, which are involved in the innate immune response reacting to exoge-
nous and endogenous stimuli by releasing inflammatory cytokines, adipokines, and other key 
mediators of Ps and atherogenesis. In addition, a consistent association was described between 
increasing obesity and lower serum 25-hydroxy vitamin D (25D) concentrations [147, 157].
In summary, chronic immune-mediated inflammation plays a key role in the pathogenesis of ath-
erosclerosis in Ps, acting independently and/or synergistically with the conventional risk factors.
Framingham risk score (FRS), which only takes into account traditional CV risk factors for 
estimating the 10-year risk of CV events like metabolic syndrome and diabetes, may under-
estimate CVR related to underlying inflammatory factors associated with this disease, also 
known as non-traditional risk factors. Improvement by inflammatory suppression argues 
strongly for immune-mediated inflammation as the central risk factor for CVD in PsA. 
However, many of the studies investigating mechanisms of PsA associated with atherogen-
esis are not definitive or conclusive enough. Larger, more systematic, and controlled studies 
are needed to confirm many of the findings previously reviewed.
9. Conclusions
Most evidence reviewed in this chapter strongly supports the hypothesis that the inflamma-
tory immune-mediated pathogenesis is probably the mayor force beyond the atherogenesis, 
from its initiation to plaque formation, rupture, and associated thrombotic complications. 
Taken together, evidence so far strongly suggests immune-mediated inflammation is the cen-
tral actor in atherogenesis beyond all risk factors, regardless of whether they are “traditional” 
or “non-traditional.” Although certain crossroads between immune-mediated inflammation 
pathways are activated in general population under cardiovascular risk conditions, it seems 
to be potentiated in psoriasis patients and other IMID. This is in agreement with accumulated 
evidence so far that indicates an enhanced CVR associated with Ps via both traditional and 
non-traditional factors immune-modulation.
Evidence so far suggests that patients with PsA and aggressive clinical presentation of Ps 
should be treated more aggressively for CVR prevention and modification. Therefore, selec-
tive long-term anti-atherosclerotic immunomodulation-oriented therapy might improve ath-
erogenesis in both general population and Ps patients.
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The existence of proatherogenic immunological pathways in CID that could damage the CV 
system reveals potential targets for more efficient therapies. This much more selective therapy 
requires long-term studies until it is available and accurate enough (Figure 2).
Abbreviations
Figure 2. Interactions between autoreactive, metabolic, and endothelial inflammation. Adipose tissue releases numerous 
inflammatory cytokines (TNF, IL6, resistin, leptin, and vistatin) that contribute to elevate systemic inflammatory burden. 
The inflammatory load is also increased by the contribution of inflammatory cytokines derived from the affected 
tissues derived autoimmune diseases. The total inflammatory load is increased only in these patients. These molecules 
perpetuate and potentiate the inflammatory process, exerting a relevant proatherogenic effect. Increased uncontrolled 
inflammation also leads to increased oxidative stress and prothrombotic risk. Then, burden psoriatic disease is likely to 
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